{
  "resourceType": "PlanDefinition",
  "id": "opioidcds-10-order-sign",
  "meta": {
    "profile": [ "http://hl7.org/fhir/uv/cpg/StructureDefinition/cpg-recommendationdefinition", "http://hl7.org/fhir/uv/cpg/StructureDefinition/cpg-publishableplandefinition" ]
  },
  "url": "http://fhir.org/guides/cdc/opioid-cds/PlanDefinition/opioidcds-10-order-sign",
  "identifier": [ {
    "use": "official",
    "value": "cdc-opioid-guidance"
  } ],
  "version": "2022.1.0",
  "name": "PlanDefinition_Recommendation_10_Order_Sign",
  "title": "Recommendation #10 - Urine Drug Testing (order-sign)",
  "type": {
    "coding": [ {
      "system": "http://terminology.hl7.org/CodeSystem/plan-definition-type",
      "code": "eca-rule",
      "display": "ECA Rule"
    } ]
  },
  "status": "draft",
  "experimental": true,
  "date": "2023-11-20",
  "publisher": "Centers for Disease Control and Prevention (CDC)",
  "description": "When prescribing opioids for subacute or chronic pain, clinicians should consider the benefits and risks of toxicology testing to assess for prescribed medications as well as other prescribed and nonprescribed controlled substances.",
  "useContext": [ {
    "code": {
      "system": "http://terminology.hl7.org/CodeSystem/usage-context-type",
      "code": "focus",
      "display": "Clinical Focus"
    },
    "valueCodeableConcept": {
      "coding": [ {
        "system": "http://snomed.info/sct",
        "code": "182888003",
        "display": "Medication requested (situation)"
      } ]
    }
  }, {
    "code": {
      "system": "http://terminology.hl7.org/CodeSystem/usage-context-type",
      "code": "focus",
      "display": "Clinical Focus"
    },
    "valueCodeableConcept": {
      "coding": [ {
        "system": "http://snomed.info/sct",
        "code": "82423001",
        "display": "Chronic pain (finding)"
      } ]
    }
  }, {
    "code": {
      "system": "http://terminology.hl7.org/CodeSystem/usage-context-type",
      "code": "focus",
      "display": "Clinical Focus"
    },
    "valueCodeableConcept": {
      "text": "Subacute pain"
    }
  } ],
  "jurisdiction": [ {
    "coding": [ {
      "system": "urn:iso:std:iso:3166",
      "code": "US",
      "display": "United States of America"
    } ]
  } ],
  "purpose": "The 2022 CDC Clinical Practice Guideline for Prescribing Opioids for Pain is intended to improve communication between clinicians and patients about the benefits and risks of pain treatments, including opioid therapy; improve the effectiveness and safety of pain treatment; mitigate pain; improve function and quality of life for patients with pain; and reduce risks associated with opioid pain therapy, including opioid use disorder, overdose, and death. The recommendations do not apply to pain related to sickle cell disease or cancer or to patients receiving palliative or end-of-life care.",
  "usage": "Before starting opioids and periodically (at least annually) during opioid therapy, clinicians should consider the benefits and risks of toxicology testing to assess for prescribed opioids and other prescription and nonprescription controlled substances that increase risk for overdose when combined with opioids, including nonprescribed and illicit opioids and benzodiazepines.",
  "copyright": "Â© CDC 2016+.",
  "topic": [ {
    "text": "Opioid Prescribing"
  } ],
  "author": [ {
    "name": "Kensaku Kawamoto, MD, PhD, MHS"
  }, {
    "name": "Bryn Rhodes"
  }, {
    "name": "Floyd Eisenberg, MD, MPH"
  }, {
    "name": "Robert McClure, MD, MPH"
  } ],
  "relatedArtifact": [ {
    "type": "documentation",
    "display": "2022 CDC Clinical Practice Guideline for Prescribing Opioids for Pain",
    "url": "https://www.cdc.gov/mmwr/volumes/71/rr/rr7103a1.htm",
    "document": {
      "contentType": "application/pdf",
      "language": "en-US",
      "url": "https://www.cdc.gov/mmwr/volumes/71/rr/pdfs/rr7103a1-H.pdf"
    }
  } ],
  "library": [ "http://fhir.org/guides/cdc/opioid-cds/Library/OpioidCDSREC10OrderSign" ],
  "action": [ {
    "prefix": "1.",
    "title": "Consider the Benefits and Risks of Conducting a Urine Toxicology Screen",
    "description": "Consider the benefits and risks of toxicology testing to assess for prescribed medications as well as other prescribed and nonprescribed controlled substances.\r\n\r\nFor guidance regarding utilizing toxicology tests when prescribing opioids, see [Recommendation 10 of the 2022 CDC Clinical Practice Guideline](https:\/\/www.cdc.gov\/mmwr\/volumes\/71\/rr\/rr7103a1.htm#:~:text=evidence%20type%3A%204).-,Implementation%20Considerations,-Toxicology%20testing%20should).",
    "priority": "urgent",
    "documentation": [ {
      "type": "documentation",
      "url": "https://www.cdc.gov/mmwr/volumes/71/rr/rr7103a1.htm#Recommendation10:~:text=nonprescribed%20controlled%20substances-,(recommendation%20category%3A%20B%3B%20evidence%20type%3A%204).,-Implementation%20Considerations",
      "document": {
        "extension": [ {
          "url": "http://hl7.org/fhir/StructureDefinition/cqf-strengthOfRecommendation",
          "valueCodeableConcept": {
            "coding": [ {
              "system": "http://terminology.hl7.org/CodeSystem/recommendation-strength",
              "code": "weak",
              "display": "Weak"
            } ]
          }
        }, {
          "url": "http://hl7.org/fhir/StructureDefinition/cqf-qualityOfEvidence",
          "valueCodeableConcept": {
            "coding": [ {
              "system": "http://terminology.hl7.org/CodeSystem/evidence-quality",
              "code": "very-low",
              "display": "Very Low quality"
            } ]
          }
        } ],
        "url": "https://www.cdc.gov/mmwr/volumes/71/rr/rr7103a1.htm#Recommendation10:~:text=nonprescribed%20controlled%20substances-,(recommendation%20category%3A%20B%3B%20evidence%20type%3A%204).,-Implementation%20Considerations"
      }
    } ],
    "trigger": [ {
      "type": "named-event",
      "name": "order-sign"
    } ],
    "condition": [ {
      "kind": "applicability",
      "expression": {
        "description": "Patient has not had a urine screening in the past 12 months",
        "language": "text/cql.identifier",
        "expression": "Is Perform Drug Screen Recommendation Applicable?"
      }
    } ],
    "type": {
      "coding": [ {
        "system": "http://terminology.hl7.org/CodeSystem/action-type",
        "code": "create",
        "display": "Create"
      } ]
    },
    "definitionCanonical": "http://fhir.org/guides/cdc/opioid-cds/ActivityDefinition/opioidcds-urine-screening-request",
    "action": [ {
      "description": "Document - Ordered toxicology screen"
    }, {
      "description": "Document - Risks outweigh benefits"
    }, {
      "description": "Snooze* - N/A see comment, snooze 3 months"
    } ]
  }, {
    "prefix": "2.",
    "title": "Patient May Have Unexpected Toxicology Test Results",
    "description": "Patient may have unexpected urine toxicology test results in the past year",
    "priority": "urgent",
    "documentation": [ {
      "type": "documentation",
      "url": "https://www.cdc.gov/mmwr/volumes/71/rr/rr7103a1.htm#Recommendation10:~:text=nonprescribed%20controlled%20substances-,(recommendation%20category%3A%20B%3B%20evidence%20type%3A%204).,-Implementation%20Considerations",
      "document": {
        "extension": [ {
          "url": "http://hl7.org/fhir/StructureDefinition/cqf-strengthOfRecommendation",
          "valueCodeableConcept": {
            "coding": [ {
              "system": "http://terminology.hl7.org/CodeSystem/recommendation-strength",
              "code": "weak",
              "display": "Weak"
            } ]
          }
        }, {
          "url": "http://hl7.org/fhir/StructureDefinition/cqf-qualityOfEvidence",
          "valueCodeableConcept": {
            "coding": [ {
              "system": "http://terminology.hl7.org/CodeSystem/evidence-quality",
              "code": "very-low",
              "display": "Very Low quality"
            } ]
          }
        } ],
        "url": "https://www.cdc.gov/mmwr/volumes/71/rr/rr7103a1.htm#Recommendation10:~:text=nonprescribed%20controlled%20substances-,(recommendation%20category%3A%20B%3B%20evidence%20type%3A%204).,-Implementation%20Considerations"
      }
    } ],
    "trigger": [ {
      "type": "named-event",
      "name": "order-sign"
    } ],
    "condition": [ {
      "kind": "applicability",
      "expression": {
        "description": "Patient may have unexpected urine toxicology test results in the past year",
        "language": "text/cql.identifier",
        "expression": "Applicable Because of Unexpected Results"
      }
    } ],
    "dynamicValue": [ {
      "path": "action.description",
      "expression": {
        "language": "text/cql.identifier",
        "expression": "Detail"
      }
    } ],
    "action": [ {
      "description": "Document - Will repeat urine drug screen more frequently"
    }, {
      "description": "Document - Will assess patient for substance use disorder"
    }, {
      "description": "Snooze* - Patient's test results were expected, snooze for 3 months"
    }, {
      "description": "Snooze* - N/A snooze for 3 months"
    } ]
  } ]
}